- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03671616
Immunogenicity and Safety of Adjuvanted Reduced Dose Inactivated Polio Vaccine Given as a Booster at Age 15-18 Months
Immunogenicity and Safety of Adjuvanted Reduced Dose Inactivated Polio Vaccine, IPV-Al SSI Given as a Booster Vaccination at the Age of 15-18 Months to Infants Previously Immunised With IPV-Al SSI or IPV SSI
Study Overview
Detailed Description
At Visit 1 (screening, blood sample, and vaccination), the subject's eligibility is assessed according to the pre-specified in-/exclusion criteria. Information on medical history, and concomitant medication are collected and a physical examination is performed and vital signs are measured (demographics data is captured from the VIPV-07 database). The health assessment of the subject will include measurement of height, weight, temperature, heart rate, respiratory rate (breathing) and a general physical examination (which can include skin, head, eyes, ears, nose, throat, heart, lungs, lymph nodes, abdomen, and the musculoskeletal system). A pre-vaccination blood sample is taken for polio antibody determinations. The subject is vaccinated with IPV-Al (and concomitant vaccine(s) according to national guidelines, if relevant) and subsequently observed for immediate adverse events 30 minutes after the vaccination. An eDiary, a thermometer and a ruler are handed out to the parent(s)/guardian(s) for measurements and recording of temperature, injection site reactions and solicited systemic adverse events (AEs). These activities are performed daily, starting on the day of the vaccination and the following 2 days and until resolved. Any other AEs are recorded in the eDiary as instructed by the trial staff. A contact to the parent(s)/guardian(s) via telephone will be made after the vaccination visit to remind and check if the parent(s)/guardian(s) have any questions regarding how to fill in the eDiary.
At Visit 2 (blood sample and trial completion), 1 month after Visit 1, the eDiary is collected, adverse events and concomitant medications are recorded, a blood sample for poliovirus antibody determination is taken and the end of the trial page is completed.
In addition to the trial vaccine, the trial subjects will receive concomitant routine childhood vaccinations. The trial vaccine is administered in the anterolateral aspect of the right thigh, whereas the other injectable childhood vaccines are administered in the left thigh.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Panama City, Panama, 0816-00383
- CEVAXIN
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Infants having completed the VIPV-07 trial
- Healthy assessed from medical history and physical examination
- Parent(s)/guardian(s), according to the local legal requirements, have been properly informed about the trial and have signed the informed consent form
- Parent(s)/guardian(s), according to the local legal requirements, have granted access to the infant's trial related medical records
- Parent(s)/guardian(s), according to the local legal requirements, are likely to comply with trial procedures
Exclusion Criteria:
- Previously vaccinated with OPV
- Previously vaccinated with IPV outside the VIPV-07 trial
- Known or suspected immunodeficiency (e.g. leukaemia or lymphoma) or family history of congenital or hereditary immunodeficiency. HIV infection is not an exclusion criterion
- Severe uncontrolled chronic disease (e.g. neurologic, pulmonary, gastrointestinal, hepatic, renal or endocrine)
- Known or suspected allergy to vaccine constituents (e.g. hypersensitivity to formaldehyde, aluminium or 2-phenoxyethanol)
- Previous Yellow Fever vaccination
- Uncontrolled coagulopathy or blood disorder contraindicating intramuscular injections or blood sampling
- In treatment with systemic corticosteroids given p.o., i.v., i.m. ≤ 1 month prior to inclusion or during the trial. Subjects administered corticosteroid topically or by asthma inhalators are eligible for inclusion
- Treatment with a product, which is likely to modify the immune response (e.g blood products and immunoglobulins) ≤ 3 months prior to inclusion or planned during the trial period
- Participating in another interventional clinical trial
- Not suitable for inclusion in the opinion of the investigator
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: IPV-Al SSI
Single arm trial.
All subjects will receive the IPV-Al SSI as booster vaccination
|
IPV-Al contains the reduced dose of IPV to be administered intramuscularly to the anterolateral of the right thigh.
A single dose of the IPV-Al SSI will be given to infants age 15-18 months.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Booster effect ratiors of GMT
Time Frame: Change from Visit 1 (6-9 months post-3rd vaccination) to one month after booster vaccination (Visit 2)
|
Booster effect (day 28 / day 0 titres), from individual serum titre values for antibodies against poliovirus types 1, 2 and 3 measured before and one month after the booster vaccination
|
Change from Visit 1 (6-9 months post-3rd vaccination) to one month after booster vaccination (Visit 2)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Seroprotection rates before booster vaccination
Time Frame: 6-9 months post-3rd vaccination
|
Subjects with seroprotection (titre ≥ 8) against poliovirus types 1, 2 and 3 before the booster vaccination.
|
6-9 months post-3rd vaccination
|
Seroprotection rates after booster vaccination
Time Frame: one month after booster vaccination
|
Subjects with seroprotection (titre ≥ 8) against poliovirus types 1, 2 and 3 one month after the booster vaccination.
|
one month after booster vaccination
|
GMT value before booster vaccination
Time Frame: 6-9 months post-3rd vaccination
|
Geometric mean antibody titres (GMTs) against poliovirus types 1, 2 and 3 before the booster vaccination.
|
6-9 months post-3rd vaccination
|
GMT value after booster vaccination
Time Frame: one month after booster vaccination
|
GMTs against poliovirus types 1, 2 and 3 one month after the booster vaccination.
|
one month after booster vaccination
|
Number of adverse events
Time Frame: 6-9 months post-3rd vaccination and one month after booster vaccination
|
All adverse event
|
6-9 months post-3rd vaccination and one month after booster vaccination
|
Persistence (tite rates) of antibodies
Time Frame: 6-9 months post-3rd vaccination and one month after booster vaccination
|
Persistence of antibodies against poliovirus types 1, 2 and 3 in subjects previously im-munised with IPV-Al SSI or IPV SSI
|
6-9 months post-3rd vaccination and one month after booster vaccination
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- VIPV-07 E1
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Poliomyelitis
-
Uniformed Services University of the Health SciencesUnknown
-
GlaxoSmithKlineCompletedPoliomyelitis | Poliomyelitis VaccinesChina
-
University Hospital, MontpellierCompletedPoliomyelitis SequelaeFrance
-
University Hospital, MontpellierCompletedPost-Poliomyélitis SyndromFrance
-
International Centre for Diarrhoeal Disease Research...Centers for Disease Control and Prevention; Government of BangladeshNot yet recruiting
-
Institut de Sante Parasport Connecte SynergiesAssistance Publique - Hôpitaux de ParisRecruiting
-
Centers for Disease Control and PreventionInternational Centre for Diarrhoeal Disease Research, BangladeshCompleted
-
Centers for Disease Control and PreventionInternational Centre for Diarrhoeal Disease Research, Bangladesh; World Health... and other collaboratorsEnrolling by invitation
-
Pierre Van DammeBill and Melinda Gates Foundation; Centers for Disease Control and Prevention; PA... and other collaboratorsCompleted
-
Sinovac Biotech Co., LtdCompleted
Clinical Trials on IPV-Al SSI
-
Statens Serum InstitutBill and Melinda Gates Foundation; Larix A/S; CCBR Clinical ResearchCompletedImmunization, BoosterDenmark
-
Statens Serum InstitutBill and Melinda Gates Foundation; Syneos Health; Larix A/S; AJ Vaccines A/SCompleted
-
Statens Serum InstitutBill and Melinda Gates Foundation; Larix A/S; Vaxtrials S.A.; AJ Vaccines A/SCompleted
-
Statens Serum InstitutQuintiles, Inc.; Bill and Melinda Gates Foundation; Larix A/SCompletedPoliomyelitisDominican Republic
-
AJ Vaccines A/SCompleted
-
Stony Brook UniversityUniversity of DenverCompletedDepressionUnited States
-
Stony Brook UniversityRecruiting
-
Radboud University Medical CenterUniversity of Southern DenmarkUnknown
-
Northwestern UniversityRecruitingDepression | Body Image | Eating DisordersUnited States
-
Stony Brook UniversityCompletedAnxietyUnited States